SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Verve Therapeutics, Inc. (VERV) .
Criteria proven by this page:
- VALUE (90/100, Pass) — analyst target implies upside (+34.8%).
- Analyst consensus target $15.00 (+34.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VERV
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio29.16
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.35
Book Value / Share$0.00
Revenue / Share$0.38
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$15.00 (+34.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.39 |
$0.00 |
$-19.02M |
- |
| 2020 |
$-0.94 |
$0.00 |
$-45.54M |
- |
| 2021 |
$-2.45 |
$0.00 |
$-118.64M |
- |
| 2022 |
$-2.91 |
$1.94M |
$-157.39M |
-8108.6% |
| 2023 |
$-3.12 |
$11.76M |
$-200.07M |
-1701.5% |
| 2024 |
$-2.35 |
$32.33M |
$-198.71M |
-614.6% |
